Author:
Zhang Yaping,Fang Hongming,Hong Jianfeng,Wang Xiaoyan,Wang Hui,Pan Guoqiang
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference23 articles.
1. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma.;Rangachari;J Thorac Oncol,2017
2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Sung;CA Cancer J Clin,2021
3. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment.;Duma;Mayo Clin Proc,2019
4. Personalized therapy for lung cancer: striking a moving target.;Pakkala;JCI Insigh,2018
5. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.;Shea;Ther Adv Respir Dis,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Dabrafenib/ensartinib;Reactions Weekly;2022-09-17